NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis $10.96 +0.49 (+4.68%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.18▼$11.2050-Day Range$5.27▼$15.4252-Week Range$4.53▼$22.49Volume369,445 shsAverage Volume1.05 million shsMarket Capitalization$122.43 millionP/E RatioN/ADividend YieldN/APrice Target$33.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Annovis Bio alerts: Email Address Annovis Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside206.6% Upside$33.60 Price TargetShort InterestBearish13.79% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.46) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector609th out of 936 stocksPharmaceutical Preparations Industry280th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingAnnovis Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnnovis Bio has only been the subject of 3 research reports in the past 90 days.Read more about Annovis Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.79% of the outstanding shares of Annovis Bio have been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annovis Bio has recently increased by 15.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANVS. Previous Next 2.2 News and Social Media Coverage News SentimentAnnovis Bio has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Annovis Bio this week, compared to 3 articles on an average week.Search Interest61 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 307% compared to the previous 30 days.MarketBeat Follows15 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders38.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.83% of the stock of Annovis Bio is held by institutions.Read more about Annovis Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($2.46) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Annovis Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Annovis Bio Stock (NYSE:ANVS)Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Read More ANVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANVS Stock News HeadlinesJuly 25 at 10:56 PM | theglobeandmail.comAnnovis Bio (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain InjuryJuly 24 at 8:00 AM | globenewswire.comAnnovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with BuntanetapJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 19, 2024 | msn.comAnnovis Bio Gains FDA Approval for New Form of Neurodegenerative DrugJuly 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team ExpansionJuly 18, 2024 | americanbankingnews.comAnnovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC WainwrightJuly 16, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Annovis Bio, Inc. (NYSE:ANVS) Lifted by HC WainwrightJuly 2, 2024 | investorplace.comWhy Did Annovis Bio (ANVS) Stock Close Up 80% Today?July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 26, 2024 | globenewswire.comAnnovis Bio Files Patent for New Composition of Matter for BuntanetapJune 11, 2024 | globenewswire.comAnnovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's PatientsMay 21, 2024 | msn.comAnnovis Bio Publishes Key Study on Posiphen Drug Across SpeciesMay 21, 2024 | globenewswire.comAnnovis Announces New Publication in a Peer-Reviewed JournalMay 17, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsMay 16, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsMay 16, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsMay 15, 2024 | benzinga.comBehind the Scenes of Annovis Bio's Latest Options TrendsMay 15, 2024 | markets.businessinsider.comBuy Rating Maintained for Annovis Bio Ahead of Key Parkinson’s Drug Trial ResultsSee More Headlines Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ANVS CUSIPN/A CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$33.60 High Stock Price Target$67.00 Low Stock Price Target$9.00 Potential Upside/Downside+206.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($5.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-876.22% Return on Assets-279.65% Debt Debt-to-Equity RatioN/A Current Ratio1.60 Quick Ratio1.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.73) per share Price / Book-15.01Miscellaneous Outstanding Shares11,171,000Free Float6,893,000Market Cap$122.43 million OptionableOptionable Beta1.74 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Maria L. Maccecchini Ph.D. (Age 73)Founder, CEO, President, Interim Principal Financial Officer & Executive Director Comp: $681.2kDr. Cheng Fang Ph.D.Senior Vice President of Research & DevelopmentMs. Eve M. Damiano M.S.RAC, Senior Vice President of Regulatory OperationsMs. Melissa GainesSenior Vice President of Clinical OperationsKey CompetitorsOculisNASDAQ:OCSAltimmuneNASDAQ:ALTRevance TherapeuticsNASDAQ:RVNCCryoportNASDAQ:CYRXEsperion TherapeuticsNASDAQ:ESPRView All CompetitorsInstitutional OwnershipCetera Advisors LLCBought 10,225 shares on 5/24/2024Ownership: 0.092%Ikarian Capital LLCBought 248,500 shares on 5/17/2024Ownership: 0.000%Affinity Asset Advisors LLCBought 72,900 shares on 5/15/2024Ownership: 0.000%Vanguard Group Inc.Bought 20,588 shares on 5/10/2024Ownership: 3.251%Redmond Asset Management LLCBought 2,077 shares on 5/7/2024Ownership: 0.328%View All Institutional Transactions ANVS Stock Analysis - Frequently Asked Questions How have ANVS shares performed this year? Annovis Bio's stock was trading at $18.70 at the beginning of 2024. Since then, ANVS shares have decreased by 41.4% and is now trading at $10.96. View the best growth stocks for 2024 here. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.15. When did Annovis Bio IPO? Annovis Bio (ANVS) raised $10 million in an IPO on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO. Who are Annovis Bio's major shareholders? Top institutional investors of Annovis Bio include Concourse Financial Group Securities Inc.. Insiders that own company stock include Reid Mccarthy, Maria-Luisa Maccecchini and Claudine Bruck. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF) and Novan (NOVN). This page (NYSE:ANVS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANVS Stock Alerts